Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: A prospective, non-randomised, single-centre study

Christopher Klenk, Rakhee Gawande, Lebriz Uslu, Aman Khurana, Deqiang Qiu, Andrew Quon, Jessica Donig, Jarrett Rosenberg, Sandra Luna-Fineman, Michael Moseley, Heike E. Daldrup-Link

Research output: Contribution to journalArticlepeer-review

127 Scopus citations


Background: Imaging tests are essential for staging of children with cancer. However, CT and radiotracer-based imaging procedures are associated with substantial exposure to ionising radiation and risk of secondary cancer development later in life. Our aim was to create a highly effective, clinically feasible, ionising radiation-free staging method based on whole-body diffusion-weighted MRI and the iron supplement ferumoxytol, used off-label as a contrast agent. Methods: We compared whole-body diffusion-weighted MRI with standard clinical 18F-fluorodeoxyglucose (18F-FDG) PET/CT scans in children and young adults with malignant lymphomas and sarcomas. Whole-body diffusion-weighted magnetic resonance images were generated by coregistration of colour-encoded ferumoxytol-enhanced whole-body diffusion-weighted MRI scans for tumour detection with ferumoxytol-enhanced T1-weighted MRI scans for anatomical orientation, similar to the concept of integrated 18F-FDG PET/CT scans. Tumour staging results were compared using Cohen's κ statistics. Histopathology and follow-up imaging served as the standard of reference. Data was assessed in the per-protocol population. This study is registered with, number NCT01542879. Findings: 22 of 23 recruited patients were analysed because one patient discontinued before completion of the whole-body scan. Mean exposure to ionising radiation was 12·5 mSv (SD 4·1) for 18F-FDG PET/CT compared with zero for whole-body diffusion-weighted MRI. 18F-FDG PET/CT detected 163 of 174 malignant lesions at 1325 anatomical regions and whole-body diffusion-weighted MRI detected 158. Comparing 18F-FDG PET/CT to whole-body diffusion-weighted MRI, sensitivities were 93·7% (95% CI 89·0-96·8) versus 90·8% (85·5-94·7); specificities 97·7% (95% CI 96·7-98·5) versus 99·5% (98·9-99·8); and diagnostic accuracies 97·2% (93·6-99·4) versus 98·3% (97·4-99·2). Tumour staging results showed very good agreement between both imaging modalities with a κ of 0·93 (0·81-1·00). No adverse events after administration of ferumoxytol were recorded. Interpretation: Ferumoxytol-enhanced whole-body diffusion-weighted MRI could be an alternative to 18F-FDG PET/CT for staging of children and young adults with cancer that is free of ionising radiation. This new imaging test might help to prevent long-term side-effects from radiographic staging procedures. Funding: Thrasher Research Fund and Clinical Health Research Institute at Stanford University.

Original languageEnglish (US)
Pages (from-to)275-285
Number of pages11
JournalThe Lancet Oncology
Issue number3
StatePublished - Mar 2014

Bibliographical note

Funding Information:
We thank Sandy Napel and Daniel Owen for their valuable input and help with magnetic resonance image data fusion. We thank Karla and Kevin Epperson and Anne Saywer at the Richard M Lucas Center for their expert help with the whole-body MRI scans. We thank Jia Wang for his assistance regarding radiation dose calculations. LU was supported as a visiting scholar by the Scientific and Technological Research Council of Turkey (TÜBİTAK).


Dive into the research topics of 'Ionising radiation-free whole-body MRI versus 18F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: A prospective, non-randomised, single-centre study'. Together they form a unique fingerprint.

Cite this